# US 2017/0362213 A1 · Nitrocatechol derivatives as comt inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362213 A1
- Document ID: US20170362213A1
- Status: Published application
- Kind: A1
- Application number: 15/402,607
- Filed: 2017-01-10
- Published: 2017-12-21
- Earliest claimed: 2005-07-26
- Assignees: Bial - Portela & Ca, S.A.
- Applicants: Bial - Portela & Ca, S.A.
- Inventors: David Alexander Learmonth; Laszlo Erno Kiss; Pedro Nuno Leal Palma; Humberto dos Santos Ferreira; Patricio Manuel V. A. Soares Da Silva
- Web page: https://patentgrep.com/patent/US20170362213A1

## CPC

- C07D 413/14: containing three or more hetero rings
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/12: Antihypertensives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/89: with hetero atoms directly attached to the ring nitrogen atom
- C07D 215/60: N-oxides
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 271/107: with two aryl or substituted aryl radicals attached in positions 2 and 5
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A process for the preparation of compounds according to formula I,
wherein X represents a methylene group; Y represents NH, or an atom of oxygen or sulphur; n represents the number 0, 1, 2 or 3; m represents the number 0 or 1; R1 and R2 independently from each other represent hydrogen, a group which is hydrolysable under physiological conditions, optionally substituted lower alkanoyl or aroyl; R3 represents a pyridine N-oxide group according to the formula A, B or C, which is connected as indicated by the unmarked bond:
and wherein P represents a central unit selected from the regioisomers of 1,3,4-oxadiazol-2,5-diyl, 1,2,4-oxadiazol-3,5-diyl, 4-methyl-4H-1,2,4-triazol-3,5-diyl, 1,3,5-triazin-2,4-diyl, 1,2,4-triazin-3,5-diyl, 2H-tetrazol-2,5-diyl, 1,2,3-thiadiazol-4,5-diyl, 1-alkyl-3-(alkoxycarbonyl)-1H-pyrrol-2,5-diyl, wherein alkyl is represented by methyl, ethyl, n-propyl and n-butyl and wherein alkoxy is represented by methoxy, ethoxy, n-propoxy and isopropoxy, 1-alkyl-1H-pyrrol-2,5-diyl wherein alkyl is represented by methyl, ethyl, n-propyl and n-butyl, thiazol-2,4-diyl, 1-H-pyrazol-1,5-diyl, pyrimidin-2,4-diyl, oxazol-2,4-diyl, carbonyl, 1H-imidazol-1,5-diyl, isoxazol-3,5-diyl, furan-2,4-diyl, 3-alkoxycarbonylfuran-2,4-diyl, wherein alkoxy is represented by methoxy, ethoxy, n-propoxy and isopropoxy, benzene-1,3-diyl and (Z)-1-cyanoethen-1,2-diyl and wherein the regioisomers of the central unit include both regioisomers realizable by exchange of the nitrocatechol moiety and the —(X)n—(Y)m—R3 moiety;
comprising steps wherein a compound of formula IIA, IIB or IIC,
wherein R4, R5, R6 and R7 independently from each other represent hydrogen, C1-C6-alkyl, C1-C6-thioalkyl, C1-C6-alkoxy, C6-C12-aryloxy, a C6-C12-thioaryl group, C1-C6-alkanoyl, a C7-C13-aroyl group, amino, C1-C6-alkylamino, C1-C6-dialkylamino, C3-C12-cycloalkylamino, C3-C12-heterocycloalkylamino, C1-C6-alkylsulphonyl, C6-C12-arylsulphonyl, halogen, C1-C6-haloalkyl, trifluoromethyl, cyano, nitro or a heteroaryl group; or where two or more of residues R4, R5, R6 and R7 taken together represent aliphatic or heteroaliphatic rings or aromatic or heteroaromatic rings,
is subjected to cyclisation with a compound of formula III,
wherein R8 and R9 independently from each other represent hydrogen or suitable protective groups for aromatic hydroxyl groups, under conditions suitable to produce oxadiazole derivatives of formula IVA, IVB or IVC,
optionally followed by removal of the protecting groups R8 and or R9.

### Claim 26

A process for the preparation of compounds according to formula I,
comprising steps wherein a compound of formula VA, VB, or VC,
wherein R4, R5, R6 and R7 independently from each other represent hydrogen, C1-C6-alkyl, C1-C6-thioalkyl, C1-C6-alkoxy, C6-C12-aryloxy, a C6-C12-thioaryl group, C1-C6-alkanoyl, a C7-C13-aroyl group, amino, C1-C6-alkylamino, C1-C6-dialkylamino, C3-C12-cycloalkylamino, C3-C12-heterocycloalkylamino, C1-C6-alkylsulphonyl, C6-C12-arylsulphonyl, halogen, C1-C6-haloalkyl, trifluoromethyl, cyano, nitro or a heteroaryl group; or where two or more of residues R4, R5, R6 and R7 taken together represent aliphatic or heteroaliphatic rings or aromatic or heteroaromatic rings,
is subjected to cyclisation with a compound of formula III under conditions suitable to produce oxadiazole derivatives of formula VIA, VIB or VIC,
followed by oxidation of the pyridyl nitrogen atom to give a compound according to formula IVA, IVB or IVC, optionally followed by removal of the protecting groups R8 and/or R9, wherein R8 and R9 independently from each other represent hydrogen or suitable protective groups for aromatic hydroxyl groups.

### Claim 27 (depends on 25)

The process according to claim 25, wherein the compound of formula III is activated by reaction with thionyl chloride or 1,1-carbonyldiimidazole.

### Claim 28 (depends on 25)

The process according to claim 25, wherein the cyclisation step consisting of condensation and dehydration is conducted sequentially in a one-pot reaction.

### Claim 29 (depends on 25)

The process according to claim 25, wherein the cyclisation step is carried out in the presence of a suitable organic base.

### Claim 30 (depends on 29)

The process according to claim 29, wherein the cyclisation step is carried out in the presence of pyridine.

### Claim 31 (depends on 25)

The process according to claim 25, wherein the groups R8 and R9 are independently from each other or jointly removed and replaced with hydrogen or a group which is hydrolysable under physiological conditions.

### Claim 32 (depends on 25)

The process according to claim 25, wherein R8 and R9 of the compound of formula III independently from each other represent methyl or hydrogen.

### Claim 33 (depends on 32)

The process according to claim 32, wherein the methyl group is removed by reaction with aluminium chloride and pyridine in N-methylpyrrolidinone.

### Claim 34 (depends on 25)

The process according to claim 25, wherein the condensation and dehydration is performed in a dipolar aprotic solvent.

### Claim 35 (depends on 34)

The process according to claim 34, wherein the condensation and dehydration is performed in dimethylacetamide, N-methylpyrrolidinone, or dimethylsulfoxide.

### Claim 36 (depends on 26)

The process according to claim 26, wherein the pyridyl nitrogen atom of the oxadiazolyl compound of formula VIA, VIB or VIC is oxidised by hydrogen peroxide, peracetic acid, trifluoroperacetic acid, or urea-hydrogen peroxide complex and trifluoroacetic anhydride.

### Claim 37 (depends on 25)

The process according to claim 25, wherein the compound of formula IIA, IIB or IIC is obtained by the reaction of compound VIIA, VIIB, or VIIC, respectively,
wherein R4, R5, R6, and R7 are defined as in the general formula I in claim 25, with hydroxylamine in the presence of a chelating agent under conditions suitable to produce amidoxime derivatives.

### Claim 38 (depends on 25, 26)

The process according to claim 26, wherein the compound of formula VA, VB or VC is obtained by the reaction of compound VIIIA, VIIIB or VIIIC, respectively,
wherein R4, R5, R6 and R7 are defined as in the general formula I in claim 25, with hydroxylamine in the presence of a chelating agent under conditions suitable to produce amidoxime derivatives.

### Claim 39 (depends on 37)

The process according to claim 37, wherein the chelating agent is selected from the group consisting of 8-hydroxyquinoline, ortho-phenanthroline and hydrates or derivatives thereof.

### Claim 40 (depends on 25)

Process for the preparation of compounds according to formula I in claim 25, comprising the oxidation of the respective pyridine compound to the pyridine N-oxide compound.
